AEON Biopharma, Inc. Operating Cash Flow
AEON Biopharma, Inc. (AEON) reported Operating Cash Flow of -$6.33 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-12
- AEON Biopharma, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$3.70M.
- AEON Biopharma, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$2.64M.
- AEON Biopharma, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$4.71M.
- AEON Biopharma, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$2.60M.
- AEON Biopharma, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$17.31M.
- AEON Biopharma, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$20.29M.
- AEON Biopharma, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$35.58M.
- AEON Biopharma, Inc. net cash provided by (used in) operating activities for fiscal 2021 was -$1.49M.
| Period end | Net Cash Provided by (Used in) Operating Activities 2 month | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 5 month | Net Cash Provided by (Used in) Operating Activities 5 month as first filed | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 7 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$3.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$6.33M 10-Q · filed 2026-08-12 | -$11.05M derived: sum of 3 quarters · filed 2026-08-12 | -$13.64M derived: sum of 4 quarters · filed 2026-08-12 | ||||||||
| 2026-03-31 | -$2.64M 10-Q · filed 2026-05-14 | -$7.35M derived: sum of 2 quarters · filed 2026-05-14 | -$9.94M derived: sum of 3 quarters · filed 2026-05-14 | -$12.04M derived: sum of 4 quarters · filed 2026-08-12 | ||||||||
| 2025-12-31 | -$4.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$7.31M derived: sum of 2 quarters · filed 2026-03-30 | -$9.40M derived: sum of 3 quarters · filed 2026-08-12 | -$17.31M 10-K · filed 2026-03-30 | ||||||||
| 2025-09-30 | -$2.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$4.69M derived: sum of 2 quarters · filed 2026-08-12 | -$12.60M 10-Q · filed 2025-11-14 | -$13.22M derived: sum of 4 quarters · filed 2026-08-12 | ||||||||
| 2025-06-30 | -$2.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$10.00M 10-Q · filed 2026-08-12 | -$10.62M derived: sum of 3 quarters · filed 2026-08-12 | -$13.58M derived: sum of 4 quarters · filed 2026-08-12 | ||||||||
| 2025-03-31 | -$7.91M 10-Q · filed 2026-05-14 | -$8.53M derived: sum of 2 quarters · filed 2026-05-14 | -$11.48M derived: sum of 3 quarters · filed 2026-05-14 | -$19.60M derived: sum of 4 quarters · filed 2026-05-14 | ||||||||
| 2024-12-31 | -$621.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$3.58M derived: sum of 2 quarters · filed 2026-03-30 | -$11.69M derived: sum of 3 quarters · filed 2026-03-30 | -$20.29M 10-K · filed 2026-03-30 | ||||||||
| 2024-09-30 | -$2.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$11.07M derived: sum of 2 quarters · filed 2025-11-14 | -$19.67M 10-Q · filed 2025-11-14 | |||||||||
| 2024-06-30 | -$8.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$16.72M 10-Q · filed 2025-08-12 | ||||||||||
| 2024-03-31 | -$8.60M 10-Q · filed 2025-05-14 | |||||||||||
| 2023-12-31 | -$26.08M 10-K · filed 2025-03-24 | -$26.08M 10-K · filed 2024-03-29 | ||||||||||
| 2023-09-30 | -$15.06M 10-Q · filed 2024-11-13 | |||||||||||
| 2023-07-21 | -$21.75M 10-K · filed 2025-03-24 | |||||||||||
| 2023-06-30 | -$10.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$21.14M 10-Q · filed 2024-08-12 | -$1.57M 10-Q · filed 2023-07-21 | -$29.60M derived: sum of 3 quarters · filed 2024-08-12 | -$56.16M derived: sum of 4 quarters · filed 2024-08-12 | |||||||
| 2023-03-31 | -$11.06M 10-Q · filed 2024-05-14 | -$623.93K 10-Q · filed 2023-05-17 | -$19.51M derived: sum of 2 quarters · filed 2024-05-14 | -$46.07M derived: sum of 3 quarters · filed 2024-05-14 | -$46.23M derived: sum of 4 quarters · filed 2024-05-14 | |||||||
| 2022-12-31 | -$8.45M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-05-14 | -$35.01M derived: sum of 2 quarters · filed 2024-05-14 | -$35.17M derived: sum of 3 quarters · filed 2024-05-14 | -$35.58M 10-K/A · filed 2024-05-14 | -$981.43K 10-K · filed 2023-02-22 | |||||||
| 2022-09-30 | -$26.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$26.72M derived: sum of 2 quarters · filed 2023-11-13 | -$27.13M 10-Q · filed 2023-11-13 | -$811.15K 10-Q · filed 2022-11-14 | -$27.29M derived: sum of 4 quarters · filed 2023-11-13 | |||||||
| 2022-06-30 | -$158.49K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-21 | -$570.15K 10-Q · filed 2023-07-21 | -$732.79K derived: sum of 3 quarters · filed 2023-07-21 | -$1.06M derived: sum of 4 quarters · filed 2023-07-21 | ||||||||
| 2022-03-31 | -$411.67K 10-Q · filed 2023-05-17 | -$574.30K derived: sum of 2 quarters · filed 2023-05-17 | -$899.62K derived: sum of 3 quarters · filed 2023-05-17 | -$1.35M derived: sum of 4 quarters · filed 2023-05-17 | ||||||||
| 2021-12-31 | -$162.63K derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-04-10 | -$487.95K derived: sum of 2 quarters · filed 2023-04-10 | -$940.27K derived: sum of 3 quarters · filed 2023-04-10 | -$1.49M 10-K/A · filed 2023-04-10 | ||||||||
| 2021-09-30 | -$325.31K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$777.64K derived: sum of 2 quarters · filed 2022-11-14 | -$1.33M 10-Q · filed 2022-11-14 | |||||||||
| 2021-06-30 | -$452.32K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | -$1.01M 10-Q · filed 2022-08-12 | ||||||||||
| 2021-03-31 | -$554.52K 10-Q · filed 2022-05-12 | $554.52K 10-Q · filed 2021-06-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |